Cargando…

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival

SIMPLE SUMMARY: Melanoma is a highly malignant skin cancer with the highest mortality of all cutaneous tumors. Relevant genetic events have been identified, which shape the tumor and also the response to treatment. Recurrent ARID1A mutations have been identified, which are associated with improved o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thielmann, Carl Maximilian, Matull, Johanna, Roth, Sebastian, Placke, Jan-Malte, Chorti, Eleftheria, Zaremba, Anne, Lodde, Georg, Jansen, Philipp, Krefting, Frederik, Kretz, Julia, Möller, Inga, Sucker, Antje, Paschen, Annette, Livingstone, Elisabeth, Zimmer, Lisa, Ugurel, Selma, Schadendorf, Dirk, Hadaschik, Eva, Griewank, Klaus G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101535/ https://www.ncbi.nlm.nih.gov/pubmed/35565222 http://dx.doi.org/10.3390/cancers14092090

Ejemplares similares

GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
por: Jansen, Philipp, et al.
Publicado: (2021)

Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi
por: Jansen, Philipp, et al.
Publicado: (2019)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions
por: Zaremba, Anne, et al.
Publicado: (2022)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study
por: Lodde, Georg Christian, et al.
Publicado: (2023)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

Analysis of SDHD promoter mutations in various types of melanoma
por: Scholz, Simone L., et al.
Publicado: (2015)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Griewank, Klaus G., et al.
Publicado: (2013)

NF1 mutations in conjunctival melanoma
por: Scholz, S. L., et al.
Publicado: (2018)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours
por: Griewank, K G, et al.
Publicado: (2013)

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
por: Stiller, Mathias, et al.
Publicado: (2016)

Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study
por: Placke, Jan-Malte, et al.
Publicado: (2021)

The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition
por: Hegedüs, Luca, et al.
Publicado: (2022)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma
por: Willmes, Christoph, et al.
Publicado: (2016)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Validating Automatic Concept-Based Explanations for AI-Based Digital Histopathology
por: Sauter, Daniel, et al.
Publicado: (2022)

Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity
por: Thier, Beatrice, et al.
Publicado: (2022)

Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection
por: Sondermann, Wiebke, et al.
Publicado: (2015)

Relevance of ARID1A Mutations in Endometrial Carcinomas
por: De Leo, Antonio, et al.
Publicado: (2022)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Therapeutic significance of ARID1A mutation in bladder cancer
por: Conde, Marina, et al.
Publicado: (2022)

Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
por: Khalique, Saira, et al.
Publicado: (2018)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report
por: Wagner, Samantha Kay, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5hklketns74g0mr4vgvjd6kbdn